The short version: I'm giving Regen-X 6 out of 10. It's the first shop in this series that gives no dose, cycle or injection instructions anywhere: when the subject comes up, its posts refuse plainly. Its trial numbers hold up, including the latest retatrutide phase 3 result, and 18 of its 19 linked papers are the right ones. But the home page says “Each batch is independently tested” and the site publishes no lab report for any of its 21 products. And the blog tells readers retatrutide shouldn't be used outside a clinical trial, then links straight to Regen-X's retatrutide vials.
What I looked at: regenx.co.za, all 12 blog posts, all 21 product pages, the shop, about, contact, FAQ, the four policies and the site's media library. All on 15 October 2026. I also checked that Regen-X has no link to us. It doesn't.
The score, broken down
| What I marked | Score | Why |
|---|---|---|
| Is it clear? | 2 / 2 | Plain language, headed sections, FAQs and short “Important” boxes. Against it: two posts still show leftover writing notes (“Suggested internal links:”), and one disclaimer names the wrong compound. Close to a 1. |
| Is it useful? | 1 / 2 | The semaglutide, retatrutide and KLOW posts genuinely help you understand trial evidence and its limits. But half the blog is benefit lists with no real sources, and the GLP-1 guides speak to patients while linking to research vials. |
| Are the facts right? | 1 / 2 | Every trial and label figure I checked holds. But two posts call GLP-1s, semaglutide and tirzepatide included, “research compounds”, when both are approved medicines. A patient guide lists injection sites the medicine labels don't. A testing lab's own marketing blog is presented as “Independent analysis”. |
| Does it show the evidence? | 1 / 2 | 18 of 19 linked papers and records are the right ones, the best ratio in the series. But 4 posts cite nothing specific, only search pages or a textbook, and a third of all links go to Wikipedia. No author is named. |
| Is it honest about downsides? | 1 / 2 | The newer posts state limits well. But SAHPRA's peptide warning appears in none of 12 posts, though it names 6 of Regen-X's products. The thyroid boxed warning is in 1 of 5 GLP-1 posts. WADA is missing from the ipamorelin post. |
| Total | 6 / 10 | Careful about doses, careless about proof. |
The supplier checks
| Check | Result | Why |
|---|---|---|
| Lab reports | Red | No lab report, lab name, batch number or verify link on any of 21 products, and none among the 73 files in the site's media library. The site still says “Each batch is independently tested” and “Certificates of Analysis are available for each product”. It fails its own five-point purity checklist. |
| Claims & dosing | Amber | No doses, cycles or reconstitution amounts anywhere, and a research-use line on every product. That's why this isn't red: dosing content drove every red so far. Against it: a five-star review on the retatrutide page describing personal weight loss, a KLOW listing selling “synergistic healing, recovery, and anti-aging benefits”, “Proven” in 10 product page titles, and a “Weight Loss Research” collection. |
| Basics | Amber | A company name and registration number on every page, a phone number, a 14-day return window, and shipping, terms and privacy pages. Missing: a street address, a VAT number, an information officer, an age limit, any research-use clause in the terms, and any mention of the 7-day cooling-off right. |
What they got right
No dosing, anywhere. Not one of 12 posts or 21 product pages gives a human dose, cycle or mixing amount. Where it comes up, the answer is a plain no: “Retatrutide does not have an approved prescribing dose because it remains investigational.” No other shop in this series has managed that.
Trial numbers that hold. The retatrutide guide reports “average weight reductions of up to 28.3% at 80 weeks” from the TRIUMPH-1 phase 3 trial, which matches Lilly's May 2026 release. The phase 2 figures match the published trial, including the heart-rate rise. The semaglutide post's STEP 1 and SELECT figures match too, and it carries the full list of label warnings.
The newer posts say the inconvenient thing. Retatrutide “should not be used outside an authorised clinical trial”. The KLOW blend “should not be described as clinically proven” synergy. Research-use products “are not approved for self-administration”. WADA status is right where it's mentioned.
A company you can identify. “Reg No 2025/979492/07” is on every page, which most shops in this series don't manage.
What dragged it down
“Independently tested”, with nothing to show. The home page says “Each batch is independently tested to verify quality and consistency”, and the purity post says “Certificates of Analysis are available for each product, with HPLC purity and mass spectrometry confirmation.” The same post sets a good standard: results should link to “a specific production run, not a product line”. I found no report on any product page or anywhere in the site's media library. The FAQ falls back to “Where available, documentation is provided on the product page or on request”.
Warns against buying it, then links to it. The retatrutide guide says it “should not be used outside an authorised clinical trial” and that “Consumers should be cautious of websites and social-media accounts claiming to sell approved reta for personal use.” Lilly, which the post cites, says retatrutide sold to consumers outside its trials is illegal. The post ends with links to Regen-X's own retatrutide vials. The semaglutide post tells readers to see a professional “rather than purchasing or using an unverified product”, then links to Regen-X's semaglutide.
Human use on a “not for human consumption” page. The retatrutide product page says “This product is not for human consumption.” and publishes a five-star review: “I've lost 9kgs in 3 months and intend to keep going!” The KLOW listing sells “synergistic healing, recovery, and anti-aging benefits”, which Regen-X's own KLOW post says it shouldn't claim. The GLP-1 guides speak to patients (“If you have been prescribed Tirzepatide”) and link to research vials.
SAHPRA's warning, missing. SAHPRA's May 2026 notice names BPC-157, TB-500, CJC-1295, ipamorelin, Selank and Semax among illegally marketed peptides, and Regen-X sells all six. It also warns that powder GLP-1s “are not registered”, and Regen-X sells powder semaglutide, tirzepatide and retatrutide. None of its 12 posts or 21 product pages mentions either.
Facts that don't hold up.
| What they say | What I found |
|---|---|
| “Glp1s are research compounds and are not approved in many jurisdictions” (R16) | Semaglutide and tirzepatide are approved medicines (Ozempic, Wegovy, Mounjaro, Zepbound). Only some GLP-1s, like retatrutide, are still investigational. |
| Injection sites in the GLP-1 guide include the glute | The Wegovy and Mounjaro labels list the abdomen, thigh or upper arm. |
| The tirzepatide guide's “Who should not use” list | Leaves out the label's boxed thyroid warning and its main contraindication (a history of medullary thyroid cancer or MEN 2). |
| “Independent analysis” found 73% of samples off on purity (R05) | The figure comes from a testing lab's own marketing blog about samples customers chose to send in, not an independent study. |
| An NCBI “overview” of how peptide research is done (R31) | The link opens a general biology textbook. |
| Retatrutide is “meaningfully ahead” of semaglutide and tirzepatide (R29) | A comparison across different trials, which Regen-X's own later post warns against. |
Sloppy publishing. The GHK-Cu post publishes its own writing brief, “Strengthen your site's topical authority by linking this article to related content” (R20), and its disclaimer is about ipamorelin (R21). One product page lists “Compound: Tirzepatide 30mg” on a 10 mg vial (R32), and glutathione appears as both 1500 mg and 15000 mg (R33).
What would get them a better grade
- Publish a lab report for each product, tied to a batch, or remove “each batch is independently tested” until they can.
- Stop linking “don't buy this outside a trial” posts to their own vials, and take down the weight-loss review.
- Fix the “Glp1s are research compounds” line, the injection sites and the missing boxed warning.
- Tell readers what SAHPRA says about the peptides they sell.
- Drop “Proven” from product titles and the KLOW healing claims.
The hardest part, no dosing, is already done. Proof is what's missing.
Their side
Regen-X can reply any time through this form. If they do, I'll add it here word for word.
Spotted something I got wrong? Tell me. I fix facts fast and say what changed. I don't change a grade because someone complains, only when I've got a fact wrong or the supplier changes what they publish.
Evidence log
| Ref | What they said | Where | Seen |
|---|---|---|---|
| R01 | “Each batch is independently tested to verify quality and consistency, giving confidence in every order.” | / · saved | 15 Oct 2026 |
| R02 | “Where available, documentation is provided on the product page or on request” | / · saved | 15 Oct 2026 |
| R03 | “Certificates of Analysis are available for each product, with HPLC purity and mass spectrometry confirmation.” | /peptide-purity-testing/ · saved | 15 Oct 2026 |
| R04 | “linking the test results to a specific production run, not a product line” | /peptide-purity-testing/ · saved | 15 Oct 2026 |
| R05 | “73% showed measurable purity discrepancies” | /peptide-purity-testing/ · saved | 15 Oct 2026 |
| R06 | “I’ve lost 9kgs in 3 months and intend to keep going!” | /product/retatrutide-30mg-research-compound/ · saved | 15 Oct 2026 |
| R07 | “This product is not for human consumption.” | /product/retatrutide-30mg-research-compound/ · saved | 15 Oct 2026 |
| R09 | “should not be used outside an authorised clinical trial” | /retatrutide-weight-loss-guide-2026/ · saved | 15 Oct 2026 |
| R10 | “Consumers should be cautious of websites and social-media accounts claiming to sell approved reta for personal use.” | /retatrutide-weight-loss-guide-2026/ · saved | 15 Oct 2026 |
| R11 | “average weight reductions of up to 28.3% at 80 weeks” | /retatrutide-weight-loss-guide-2026/ · saved | 15 Oct 2026 |
| R12 | “Retatrutide does not have an approved prescribing dose because it remains investigational.” | /retatrutide-weight-loss-guide-2026/ · saved | 15 Oct 2026 |
| R13 | “Phase 2 research also observed dose-dependent increases in heart rate.” | /retatrutide-weight-loss-guide-2026/ · saved | 15 Oct 2026 |
| R14 | “rather than purchasing or using an unverified product” | /semaglutide-for-weight-loss/ · saved | 15 Oct 2026 |
| R15 | “US prescribing information carries a boxed warning based on tumours seen in rodents.” | /semaglutide-for-weight-loss/ · saved | 15 Oct 2026 |
| R16 | “Glp1s are research compounds and are not approved in many jurisdictions” | /glp-1-weight-loss-injections/ · saved | 15 Oct 2026 |
| R17 | “Follow the dosing schedule prescribed by your healthcare professional” | /glp-1-weight-loss-injections/ · saved | 15 Oct 2026 |
| R18 | “If you have been prescribed Tirzepatide, your healthcare team may recommend:” | /tirzepatide-benefits-weight-loss/ · saved | 15 Oct 2026 |
| R19 | “Signs of pancreatitis, such as severe abdominal pain that may radiate to the back.” | /tirzepatide-benefits-weight-loss/ · saved | 15 Oct 2026 |
| R20 | “Strengthen your site’s topical authority by linking this article to related content” | /ghk-cu-peptide-guide/ · saved | 15 Oct 2026 |
| R21 | “Ipamorelin is a research compound and is not approved in many jurisdictions” | /ghk-cu-peptide-guide/ · saved | 15 Oct 2026 |
| R22 | “This combination should not be described as clinically proven” | /klow-80-peptide-blend/ · saved | 15 Oct 2026 |
| R23 | “The 2026 WADA Prohibited List includes BPC-157 and thymosin beta-4 derivatives such as TB-500 within prohibited categories.” | /klow-80-peptide-blend/ · saved | 15 Oct 2026 |
| R24 | “Suggested internal links:” | /klow-80-peptide-blend/ · saved | 15 Oct 2026 |
| R25 | “for synergistic healing, recovery, and anti-aging benefits” | /product/klow-stack/ · saved | 15 Oct 2026 |
| R26 | “Competitive athletes should also be aware that MOTS-c is prohibited under anti-doping rules” | /mots-c-peptide-benefits/ · saved | 15 Oct 2026 |
| R27 | “are not approved for self-administration” | /mots-c-peptide-benefits/ · saved | 15 Oct 2026 |
| R28 | “Faster recovery between training sessions” | /ipamorelin-southafrica-informationforsale/ · saved | 15 Oct 2026 |
| R29 | “this places retatrutide meaningfully ahead of both Semaglutide” | /retatrutide-research-overview/ · saved | 15 Oct 2026 |
| R30 | “Kisspeptin 10mg is available from ReGen-X for laboratory research use.” | /nootropic-peptides-research/ · saved | 15 Oct 2026 |
| R31 | “this overview from the National Center for Biotechnology Information (NCBI)” | /what-are-peptides/ · saved | 15 Oct 2026 |
| R32 | “Compound: Tirzepatide 30mg” | /product/tirzepatide-10mg/ · saved | 15 Oct 2026 |
| R33 | “Glutathione 15000mg is a tripeptide antioxidant” | /product/glutathione-15000mg/ · saved | 15 Oct 2026 |
| R34 | “Weight Loss Research” | /shop/ · saved | 15 Oct 2026 |
| R35 | “admin@regenx.co.za” | /contact-regen-x/ · saved | 15 Oct 2026 |
| R36 | “Reg No 2025/979492/07” | /contact-regen-x/ · saved | 15 Oct 2026 |
| R37 | “Return requests must be submitted within 14 days of delivery.” | /refund_returns/ · saved | 15 Oct 2026 |
| R38 | “including POPIA where applicable” | /privacy-policy/ · saved | 15 Oct 2026 |
Update log
- 15 Oct 2026: First published.
